Skip to Content

Poliovirus vaccine, live, trivalent Disease Interactions

There are 2 disease interactions with poliovirus vaccine, live, trivalent:

Major

Polio vaccine (live oral) (applies to poliovirus vaccine, live, trivalent) immunodeficiency

Major Potential Hazard, High plausibility.

In general, the use of poliovirus vaccine (live oral trivalent) is contraindicated in patients with primary or acquired immunodeficiency or infection with HIV. Since the vaccine contains live attenuated virus, the absence of immune competence may potentiate the replication of vaccine virus, increase adverse host reactions, and compromise serum antibody response. Likewise, the vaccine should not be given to anyone with a family history of congenital or hereditary immunodeficiency until the individual's immune status can be assessed and is determined to be adequate. Finally, poliovirus vaccine (live oral trivalent) should not be administered to any household member of immunodeficient or HIV-infected persons because the recipient can shed vaccine viruses in the feces for up to 6 to 8 weeks after administration, and by the pharyngeal route for 1 to 2 weeks. Polio immunization for all members of the groups described above should utilize enhanced inactivated poliovirus vaccine (eIPV). Incidentally, in an effort to eliminate the risk of vaccine-associated paralytic polio, the Advisory Committee on Immunization Practices now recommends an all-IPV schedule (except under special circumstances) for routine childhood polio vaccination in the United States. As of January 1, 2000, all children should receive four doses of IPV at ages 2 months, 4 months, 6-18 months, and 4-6 years.

References

  1. Centers for Disease Control and Prevention "Notice to readers: recommendations of the advisory committtee on immunization proctices: revised recommendations for routine poliomyelitis vaccination." MMWR Morb Mortal Wkly Rep 48 (1999): 590
  2. "Product Information. Orimune (poliovirus vaccine, live, oral, trivalent)." Lederle Laboratories, Philadelphia, PA.
  3. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
Major

Vaccination (applies to poliovirus vaccine, live, trivalent) infections

Major Potential Hazard, High plausibility. Applicable conditions: Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Varivax (varicella virus vaccine live)." Merck & Co, Inc, West Point, PA.
  4. "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.
  5. "Product Information. Typhim Vi (typhoid vaccine)." Connaught, Swiftwater, PA.
  6. "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.
  7. "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.
  8. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
  9. "Product Information. Menomune-A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught, Swiftwater, PA.
  10. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
  11. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  12. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  13. "Product Information. Orimune (poliovirus vaccine, live, oral, trivalent)." Lederle Laboratories, Philadelphia, PA.
  14. "Product Information. Mumpsvax (mumps virus vaccine (live).)." Merck & Co, Inc, West Point, PA.
  15. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
View all 15 references

Poliovirus vaccine, live, trivalent drug interactions

There are 249 drug interactions with poliovirus vaccine, live, trivalent

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.